FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2593027440> ?p ?o ?g. }

• W2593027440 abstract "Reactivation of occult or inactive Hepatitis B virus (HBV) infection during immunosuppressant treatments is well known and widely described in literature. The same observation has been made in Hepatitis C (HCV)-infected patients previously exposed to HBV and treated with interferon-free DAA treatments. Because of common transmission routes, persons may have been exposed to HCV, HBV and HIV, but few cases have been reported in this scenario to date. Frequency of HBV reactivation in HIV/HCV co-infected patients previously exposed to HBV and treated with DAA remains unclear. Herein, we report an episode of HBV reactivation in an HIV/HCV co-infected patient prescribed with sofosbuvir/ledipasvir for HCV.The patient is a Caucasian 54-years old female, with HIV/HCV co-infection (genotype 4), and a previous exposure to HBV, documented by negativity of HBsAg and positivity of HBsAb and HBcAb. Her medical history included: myocardial infarct, chronic kidney disease stage 3, chronic obstructive pulmonary disease, and mild pulmonary hypertension. HCV had not been treated with interferon (IFN)-based regimens and liver stiffness was 10.5 KPa (Metavir stage F3) at hepatic elastography. Because of CKD, she was prescribed with a nucleoside reverse transcriptase (NRTI)-sparing regimen including darunavir/ritonavir plus etravirine, and thereafter with sofosbuvir/ledipasvir for 12 weeks. Four weeks after DAA termination, the patient was hospitalized with symptoms of acute hepatitis. Blood tests showed HCV RNA <12 IU/ml, but positivity of HBAg, HBeAg, and of anti-core antibodies (IgM and IgG), while anti-HBs and anti-HBe antibodies were negative. HBV DNA was 6.06 Log10 IU/ml. Entecavir was started obtaining resolution of symptoms, normalization of liver enzymes, as well as reduction of HBV DNA and of quantitative HBV surface antigen.This case-report highlights the risk of HBV reactivation with interferon-free DAA treatment in HIV/HCV co-infected patients previously exposed to HBV and who have contraindications for treatment with nucleoside/nucleotide reverse transcriptase Inhibitors because of comorbid conditions. In the setting of HIV infection, clinicians prescribing DAA should be aware of this risk, and HBV assessment at treatment start as well as virological monitoring during DAA treatment is recommended. Large epidemiological and virological studies are needed to investigate reactivation of occult HBV infection more in depth." @default.
• W2593027440 created "2017-03-16" @default.
• W2593027440 creator A5001643890 @default.
• W2593027440 creator A5003231872 @default.
• W2593027440 creator A5024762087 @default.
• W2593027440 creator A5029340348 @default.
• W2593027440 creator A5032359240 @default.
• W2593027440 creator A5058420241 @default.
• W2593027440 creator A5064636041 @default.
• W2593027440 creator A5068794283 @default.
• W2593027440 creator A5075357953 @default.
• W2593027440 date "2017-03-01" @default.
• W2593027440 modified "2023-10-16" @default.
• W2593027440 title "Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature" @default.
• W2593027440 cites W1961676249 @default.
• W2593027440 cites W1978670933 @default.
• W2593027440 cites W1979176407 @default.
• W2593027440 cites W2015071219 @default.
• W2593027440 cites W2024122432 @default.
• W2593027440 cites W2029731887 @default.
• W2593027440 cites W2034101072 @default.
• W2593027440 cites W2095096270 @default.
• W2593027440 cites W2102184285 @default.
• W2593027440 cites W2137218964 @default.
• W2593027440 cites W2138989020 @default.
• W2593027440 cites W2161026901 @default.
• W2593027440 cites W2171698165 @default.
• W2593027440 cites W2272847213 @default.
• W2593027440 cites W2278142396 @default.
• W2593027440 cites W2291793254 @default.
• W2593027440 cites W2340901454 @default.
• W2593027440 cites W2467251948 @default.
• W2593027440 cites W2468831713 @default.
• W2593027440 cites W2470344850 @default.
• W2593027440 cites W2487128818 @default.
• W2593027440 cites W3150885765 @default.
• W2593027440 cites W781571009 @default.
• W2593027440 doi "https://doi.org/10.1186/s12879-017-2287-y" @default.
• W2593027440 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5333431" @default.
• W2593027440 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28249574" @default.
• W2593027440 hasPublicationYear "2017" @default.
• W2593027440 type Work @default.
• W2593027440 sameAs 2593027440 @default.
• W2593027440 citedByCount "23" @default.
• W2593027440 countsByYear W25930274402017 @default.
• W2593027440 countsByYear W25930274402018 @default.
• W2593027440 countsByYear W25930274402019 @default.
• W2593027440 countsByYear W25930274402020 @default.
• W2593027440 countsByYear W25930274402021 @default.
• W2593027440 countsByYear W25930274402022 @default.
• W2593027440 crossrefType "journal-article" @default.
• W2593027440 hasAuthorship W2593027440A5001643890 @default.
• W2593027440 hasAuthorship W2593027440A5003231872 @default.
• W2593027440 hasAuthorship W2593027440A5024762087 @default.
• W2593027440 hasAuthorship W2593027440A5029340348 @default.
• W2593027440 hasAuthorship W2593027440A5032359240 @default.
• W2593027440 hasAuthorship W2593027440A5058420241 @default.
• W2593027440 hasAuthorship W2593027440A5064636041 @default.
• W2593027440 hasAuthorship W2593027440A5068794283 @default.
• W2593027440 hasAuthorship W2593027440A5075357953 @default.
• W2593027440 hasBestOaLocation W25930274401 @default.
• W2593027440 hasConcept C126322002 @default.
• W2593027440 hasConcept C159047783 @default.
• W2593027440 hasConcept C203014093 @default.
• W2593027440 hasConcept C2522874641 @default.
• W2593027440 hasConcept C2775940106 @default.
• W2593027440 hasConcept C2775999097 @default.
• W2593027440 hasConcept C2776408679 @default.
• W2593027440 hasConcept C2776455275 @default.
• W2593027440 hasConcept C2777410769 @default.
• W2593027440 hasConcept C2778390639 @default.
• W2593027440 hasConcept C2780040827 @default.
• W2593027440 hasConcept C2780593183 @default.
• W2593027440 hasConcept C71924100 @default.
• W2593027440 hasConcept C90924648 @default.
• W2593027440 hasConceptScore W2593027440C126322002 @default.
• W2593027440 hasConceptScore W2593027440C159047783 @default.
• W2593027440 hasConceptScore W2593027440C203014093 @default.
• W2593027440 hasConceptScore W2593027440C2522874641 @default.
• W2593027440 hasConceptScore W2593027440C2775940106 @default.
• W2593027440 hasConceptScore W2593027440C2775999097 @default.
• W2593027440 hasConceptScore W2593027440C2776408679 @default.
• W2593027440 hasConceptScore W2593027440C2776455275 @default.
• W2593027440 hasConceptScore W2593027440C2777410769 @default.
• W2593027440 hasConceptScore W2593027440C2778390639 @default.
• W2593027440 hasConceptScore W2593027440C2780040827 @default.
• W2593027440 hasConceptScore W2593027440C2780593183 @default.
• W2593027440 hasConceptScore W2593027440C71924100 @default.
• W2593027440 hasConceptScore W2593027440C90924648 @default.
• W2593027440 hasIssue "1" @default.
• W2593027440 hasLocation W25930274401 @default.
• W2593027440 hasLocation W25930274402 @default.
• W2593027440 hasLocation W25930274403 @default.
• W2593027440 hasLocation W25930274404 @default.
• W2593027440 hasOpenAccess W2593027440 @default.
• W2593027440 hasPrimaryLocation W25930274401 @default.
• W2593027440 hasRelatedWork W1494523999 @default.
• W2593027440 hasRelatedWork W2287220040 @default.
• W2593027440 hasRelatedWork W2420993274 @default.
• W2593027440 hasRelatedWork W2560819825 @default.

• next